Is Hims & Hers Health (HIMS) Attractive After The Recent Share Price Pullback [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
If you are wondering whether Hims & Hers Health at US$25.54 still offers value after its big run in recent years, this article walks through what the current price might be implying. The stock has seen a 13.9% decline over the last 7 days, a 23.6% decline over the last 30 days, and is down 23.6% year to date, although the 3 year return is very large and the 5 year return sits at 8.7%. These moves have come alongside growing attention on digital health platforms that aim to make access to treatments more direct for consumers, and on how such business models are being valued relative to more traditional healthcare names. That backdrop helps explain why Hims & Hers Health has seen periods of strong enthusiasm followed by sharper pullbacks as investors reassess what they are willing to pay. On our checks, Hims & Hers Health scores 2 out of 6 for potential undervaluation. Next we will look at what different valuation methods are saying about that score, and then finish with a way to
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- FDA to restrict GLP-1 ingredients used in non-approved compounded drugs [CNBC]CNBC
- FDA to restrict GLP-1 ingredients used in non-approved compounded drugs [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly, Novo down as Hims to offer cheaper weight-loss pill [Seeking Alpha]Seeking Alpha
- Hims and Hers Health's compounded Wegovy pill offering fuels market jitters [Yahoo! Finance]Yahoo! Finance
- Instant View: Hims and Hers Health's compounded Wegovy pill offering fuels market jitters [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 2/4/26 - Form 4
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- HIMS's page on the SEC website